查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570724

晚期復發性卵巢癌市場：依疾病類型、治療類型分類 - 全球預測 2025-2030

Advanced Recurrent Ovarian Cancer Market by Disease Type (Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer), Treatment Type (Chemotherapy, Hormonal Therapy, Targeted Therapy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年晚期復發性卵巢癌市值為14.3億美元，預計2024年將達15.3億美元，複合年成長率為9.15%，到2030年將達到26.4億美元。

晚期復發性卵巢癌市場的範圍和定義包括疾病進展和復發的研究，重點是治療和診斷的進展。這個市場需要了解患者的需求、治療效果和醫療保健提供者的要求。市場開拓研究的應用對於藥物開發、設計有效的治療方法、改進早期檢測方法和加強患者照護至關重要。最終用途包括製藥公司、生物技術公司、研究機構以及直接參與診斷和治療的醫療保健提供者。影響成長的關鍵因素包括生物技術的進步、個人化醫療、卵巢癌盛行率的增加以及對有效治療方案不斷成長的需求。投資研發、生物技術公司之間的合作以及利用人工智慧進行藥物發現都是主要的商機。特別是，正在進行的 PARP 抑制劑和免疫腫瘤治療研究有可能帶來突破。然而，高昂的治療成本、嚴格的監管要求以及先進治療意識有限等限制因素給市場拓展帶來了挑戰。此外，與抗治療性和患者反應變異相關的問題需要持續創新。公司可以探索一些領域，例如開發針對基因圖譜的標靶治療以及增強伴同性診斷工具以改善治療方法配對。改善現有藥物的安全性和盡量減少副作用的研究也將推動成長。市場的本質是動態的，並受到技術進步和監管環境的影響，這要求公司保持敏捷。研究表明，將優先考慮與研究機構合作進行協作研究，投資資料分析以更好地預測結果，並專注於以患者為中心的方法來提高患者的參與度。總體而言，治療方法和患者管理策略的創新對於該市場的業務成長仍然至關重要。

主要市場統計
基準年[2023] 14.3億美元
預測年份 [2024] 15.3億美元
預測年份 [2030] 26.4億美元
複合年成長率（%） 9.15%

市場動態：揭示快速發展的晚期復發性卵巢癌市場的關鍵市場洞察

供需的動態交互作用正在改變晚期復發性卵巢癌市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，以及消費行為及其對製造成本的影響及其對採購趨勢的影響。

波特五力：駕馭晚期復發性卵巢癌市場的策略工具

波特的五力框架是了解晚期復發性卵巢癌市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解晚期復發性卵巢癌市場的外部影響

外部宏觀環境因素在塑造晚期復發性卵巢癌市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解晚期復發性卵巢癌市場的競爭格局

對晚期復發性卵巢癌市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣高階復發性卵巢癌市場供應商的績效評估

FPNV定位矩陣是評估晚期復發性卵巢癌市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為晚期復發性卵巢癌市場制定成功之路

對於旨在加強在全球市場的影響力的公司來說，晚期復發性卵巢癌市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告提供了涵蓋主要焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 專門針對復發性卵巢癌的標靶治療的開發和核准增加
      • 擴大臨床試驗計劃，重點關注晚期和復發性卵巢癌的創新治療方法
      • 透過製藥公司和研究機構之間的合作推廣新治療方法
      • 增加對個人化醫療的投資有助於促進復發性卵巢癌的有效治療策略
    • 抑制因素
      • 晚期復發性卵巢癌的早期診斷和缺乏特異性生物標記
      • 目前晚期復發性卵巢癌治療通訊協定相關的副作用和毒性
    • 機會
      • 應用人工智慧和機器學習預測晚期復發性卵巢癌的治療反應和結果
      • 為醫療保健專業人員開發晚期復發性卵巢的教育計劃和資源
      • 晚期復發性卵巢癌將患者報告的結果和真實世界的證據整合到臨床試驗中，以實現更個人化的治療
    • 任務
      • 確保為晚期和復發性卵巢癌研究提供充足的資金和資源
      • 解決晚期和復發性卵巢癌治療的患者可近性和負擔能力問題。
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章晚期復發性卵巢癌市場：依疾病類型

  • 介紹
  • 上皮性卵巢癌
    • 透明細胞
    • 子宮內膜樣
    • 黏液
    • 漿液性的
  • 非上皮性卵巢癌
    • 生殖細胞腫瘤
    • 間質瘤

第7章晚期復發性卵巢癌市場：依治療類型

  • 介紹
  • 化療
    • 非鉑類化療
      • 多西紫杉醇
      • 紫杉醇
    • 含鉑類藥物化療
      • Carboplatin
      • Cisplatin
  • 荷爾蒙療法
    • 來曲唑
    • 他莫昔芬
  • 標靶治療
    • 抗血管新生劑
      • Bevacizumab
    • PARP抑制劑
      • 尼拉帕尼
      • 奧拉帕尼
      • 盧卡帕尼

第8章北美和南美晚期復發性卵巢癌市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太晚期復發性卵巢癌市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的晚期復發性卵巢癌市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064BFFBB

The Advanced Recurrent Ovarian Cancer Market was valued at USD 1.43 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 9.15%, to USD 2.64 billion by 2030.

The scope and definition of the market for advanced recurrent ovarian cancer involve the study of the disease's progression and reoccurrence, focusing on therapeutic and diagnostic advancements. This market encompasses the necessity to understand patient needs, treatment efficacy, and healthcare provider requirements. Applications of market research here are crucial for drug development, crafting effective therapies, improving early detection methods, and enhancing patient care. End-use scope extends to pharmaceutical companies, biotechnology firms, research institutions, and healthcare providers who directly engage with diagnosis and treatment. Key influencing growth factors include advancements in biotechnology, personalized medicine, increasing prevalence of ovarian cancer, and rising demand for effective treatment options. Investment in R&D, collaborations between biotech firms, and leveraging AI for drug discovery represent significant opportunities. Particularly, ongoing research into PARP inhibitors and immune-oncology therapies presents potential breakthroughs. However, limitations such as high treatment costs, stringent regulatory requirements, and limited awareness about advanced therapies pose challenges to market expansion. Furthermore, issues related to treatment resistance and variability in patient response necessitate continuous innovation. Businesses can explore areas like the development of targeted therapies tailored to genetic profiles or the enhancement of companion diagnostic tools for improved treatment matching. Research into improving the safety profiles of existing drugs and minimizing side effects can also drive growth. The nature of the market is dynamic, influenced by technological advancements and regulatory landscapes, requiring firms to stay agile. Insights suggest prioritizing partnerships with research institutions for collaborative studies, investing in data analytics for better outcome predictions, and focusing on patient-centric approaches to drive engagement. Overall, innovation in treatment modalities and patient management strategies remains pivotal for business growth in this market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.53 billion
Forecast Year [2030] USD 2.64 billion
CAGR (%) 9.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Advanced Recurrent Ovarian Cancer Market

The Advanced Recurrent Ovarian Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing development and approval of targeted therapies specifically for recurrent ovarian cancer
    • Expanding clinical trial programs focused on innovative treatments for advanced recurrent ovarian cancer
    • Collaborations between pharmaceutical companies and research institutions advancing novel treatment approaches
    • Increasing investment in personalized medicine boosting effective treatment strategies for recurrent ovarian cancer
  • Market Restraints
    • Lack of early diagnosis and specific biomarkers for advanced recurrent ovarian cancer
    • Adverse side effects and toxicity associated with current treatment protocols for advanced recurrent ovarian cancer
  • Market Opportunities
    • Application of artificial intelligence and machine learning in predicting treatment responses and outcomes for advanced recurrent ovarian cancer
    • Development of educational programs and resources for healthcare professionals specializing in advanced recurrent ovarian cancer
    • Integration of patient-reported outcomes and real-world evidence into clinical trials for more personalized therapy in advanced recurrent ovarian cancer
  • Market Challenges
    • Ensuring adequate funding and resources for advanced recurrent ovarian cancer research
    • Addressing patient accessibility and affordability of advanced recurrent ovarian cancer therapies.

Porter's Five Forces: A Strategic Tool for Navigating the Advanced Recurrent Ovarian Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Advanced Recurrent Ovarian Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Advanced Recurrent Ovarian Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Advanced Recurrent Ovarian Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Advanced Recurrent Ovarian Cancer Market

A detailed market share analysis in the Advanced Recurrent Ovarian Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Advanced Recurrent Ovarian Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Advanced Recurrent Ovarian Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Advanced Recurrent Ovarian Cancer Market

A strategic analysis of the Advanced Recurrent Ovarian Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Advanced Recurrent Ovarian Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Genentech, GSK, ImmunoGen, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Seagen, Tesaro, and Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Advanced Recurrent Ovarian Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Epithelial Ovarian Cancer and Non-Epithelial Ovarian Cancer. The Epithelial Ovarian Cancer is further studied across Clear Cell, Endometrioid, Mucinous, and Serous. The Non-Epithelial Ovarian Cancer is further studied across Germ Cell Tumors and Stromal Tumors.
  • Based on Treatment Type, market is studied across Chemotherapy, Hormonal Therapy, and Targeted Therapy. The Chemotherapy is further studied across Non-Platinum Chemotherapy and Platinum-Based Chemotherapy. The Non-Platinum Chemotherapy is further studied across Docetaxel and Paclitaxel. The Platinum-Based Chemotherapy is further studied across Carboplatin and Cisplatin. The Hormonal Therapy is further studied across Letrozole and Tamoxifen. The Targeted Therapy is further studied across Anti-Angiogenic Agents and PARP Inhibitors. The Anti-Angiogenic Agents is further studied across Bevacizumab. The PARP Inhibitors is further studied across Niraparib, Olaparib, and Rucaparib.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing development and approval of targeted therapies specifically for recurrent ovarian cancer
      • 5.1.1.2. Expanding clinical trial programs focused on innovative treatments for advanced recurrent ovarian cancer
      • 5.1.1.3. Collaborations between pharmaceutical companies and research institutions advancing novel treatment approaches
      • 5.1.1.4. Increasing investment in personalized medicine boosting effective treatment strategies for recurrent ovarian cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of early diagnosis and specific biomarkers for advanced recurrent ovarian cancer
      • 5.1.2.2. Adverse side effects and toxicity associated with current treatment protocols for advanced recurrent ovarian cancer
    • 5.1.3. Opportunities
      • 5.1.3.1. Application of artificial intelligence and machine learning in predicting treatment responses and outcomes for advanced recurrent ovarian cancer
      • 5.1.3.2. Development of educational programs and resources for healthcare professionals specializing in advanced recurrent ovarian cancer
      • 5.1.3.3. Integration of patient-reported outcomes and real-world evidence into clinical trials for more personalized therapy in advanced recurrent ovarian cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Ensuring adequate funding and resources for advanced recurrent ovarian cancer research
      • 5.1.4.2. Addressing patient accessibility and affordability of advanced recurrent ovarian cancer therapies.
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Advanced Recurrent Ovarian Cancer Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Epithelial Ovarian Cancer
    • 6.2.1. Clear Cell
    • 6.2.2. Endometrioid
    • 6.2.3. Mucinous
    • 6.2.4. Serous
  • 6.3. Non-Epithelial Ovarian Cancer
    • 6.3.1. Germ Cell Tumors
    • 6.3.2. Stromal Tumors

7. Advanced Recurrent Ovarian Cancer Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
    • 7.2.1. Non-Platinum Chemotherapy
      • 7.2.1.1. Docetaxel
      • 7.2.1.2. Paclitaxel
    • 7.2.2. Platinum-Based Chemotherapy
      • 7.2.2.1. Carboplatin
      • 7.2.2.2. Cisplatin
  • 7.3. Hormonal Therapy
    • 7.3.1. Letrozole
    • 7.3.2. Tamoxifen
  • 7.4. Targeted Therapy
    • 7.4.1. Anti-Angiogenic Agents
      • 7.4.1.1. Bevacizumab
    • 7.4.2. PARP Inhibitors
      • 7.4.2.1. Niraparib
      • 7.4.2.2. Olaparib
      • 7.4.2.3. Rucaparib

8. Americas Advanced Recurrent Ovarian Cancer Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Advanced Recurrent Ovarian Cancer Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Advanced Recurrent Ovarian Cancer Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bristol-Myers Squibb
  • 5. Clovis Oncology
  • 6. Eli Lilly and Company
  • 7. Exelixis
  • 8. Genentech
  • 9. GSK
  • 10. ImmunoGen
  • 11. Johnson & Johnson
  • 12. Merck & Co.
  • 13. Novartis
  • 14. Pfizer
  • 15. Regeneron Pharmaceuticals
  • 16. Roche
  • 17. Sanofi
  • 18. Seagen
  • 19. Tesaro
  • 20. Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. ADVANCED RECURRENT OVARIAN CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ADVANCED RECURRENT OVARIAN CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ADVANCED RECURRENT OVARIAN CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADVANCED RECURRENT OVARIAN CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADVANCED RECURRENT OVARIAN CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ENDOMETRIOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY MUCINOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SEROUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY GERM CELL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LETROZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TAMOXIFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 236. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 239. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 246. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 247. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 249. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 267. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 269. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 270. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 273. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 278. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 280. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
  • TABLE 281. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY